LH Earnings Date: Feb 16, 2027 (Estimated) — Labcorp Holdings Inc.
NYSE · Healthcare · Diagnostics & Research
Updated
When is LH's next earnings date?
Labcorp Holdings Inc. (LH) is expected to report Q4 2026 earnings on Tuesday, February 16, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $4.45 on revenue of $3.72B.
How did LH do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), Labcorp Holdings Inc. posted EPS of $4.78 versus the $4.64 estimate, a beat of 3.0%. Revenue was $3.81B against a $3.76B estimate. The stock's 1-day post-earnings move was +8.8%.
How much does LH stock move after earnings?
LH beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.7% (up or down) in the day after earnings.
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
🤖 AI Earnings Analysis
Labcorp’s 6.9% revenue growth and expanded access to FDA-approved HPV screening support a strong diagnostics outlook; management raised 2026 guidance. Reported EPS figures conflict ($4.78 versus $3.22 in the headline), tempering confidence in the beat.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | 4.64 | 4.78 | +3.02% | $3.81B | ✅ Beat | +8.78% | — | — |
| 2026-07-30 | Q2 2026 | 4.78 | 4.99 | +4.39% | $3.73B | ✅ Beat | +2.73% | +2.22% | +9.57% |
| 2026-04-30 | Q1 2026 | 4.11 | 4.25 | +3.41% | $3.54B | ✅ Beat | -0.13% | -0.08% | +1.41% |
| 2026-02-17 | Q4 2025 | 3.95 | 4.07 | +3.04% | $3.52B | ✅ Beat | -2.11% | +0.94% | -4.01% |
| 2025-10-28 | Q3 2025 | 4.13 | 4.18 | +1.21% | $3.56B | ✅ Beat | -5.79% | -6.46% | -2.11% |
| 2025-04-29 | Q1 2025 | 4.17 | 3.84 | -7.91% | $3.35B | ❌ Miss | +4.72% | +7.50% | +7.59% |
| 2025-02-06 | Q4 2024 | 3.39 | 3.45 | +1.77% | $3.33B | ✅ Beat | -0.90% | -3.54% | +1.50% |
| 2024-10-24 | Q3 2024 | 3.49 | 3.50 | +0.29% | $3.28B | ✅ Beat | +4.63% | +4.85% | +9.22% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $3.74B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| LabCorp Diagnostics | 77.6% | $2.90B | +5.5% | $2.59B | $2.63B | $2.75B | $2.77B |
| Biopharma Laboratory Services | 22.4% | $836.2M | — | — | $721.3M | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.